Esperion Therapeutics: Q4 Earnings Snapshot
Esperion Therapeutics: Q3 Earnings Snapshot
Esperion Therapeutics: Q2 Earnings Snapshot
Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -21.54% and 15.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics: Q1 Earnings Snapshot
Stevanato (STVN) delivered earnings and revenue surprises of -7.69% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.
March S&P 500 futures (ESH23) are down -0.10%, and March Nasdaq 100 E-Mini futures (NQH23) are up +0.21% this morning after three major U.S. benchmark indices ended the regular session mixed as signs of...